Recent developments in myeloid immune modulation in cancer therapy

Trends in cancer, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Adoptive T Cell Therapy Targeting MAGE-A4

Cancers, Journal Year: 2025, Volume and Issue: 17(3), P. 413 - 413

Published: Jan. 26, 2025

MAGE A4 (Melanoma Antigen Gene A4) is a cancer testis antigen (CTA) that expressed normally in germline cells (testis/embryonic tissues) but absent somatic cells. The CTA variety of tumor types, like synovial sarcoma, ovarian and non-small cell lung cancer. Having its expression profile limited to has made sought-after immunotherapeutic target certain malignancies. In this review, we focus on MAGE-A4’s function expression, current clinical trials involving targeted immunotherapy approaches, challenges opportunities facing therapeutics.

Language: Английский

---

Gold Nanoparticles Synthesized with Triple-Negative Breast Cancer Cell Lysate Enhance Antitumoral Immunity: A Novel Synthesis Method

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(3), P. 330 - 330

Published: Feb. 26, 2025

Background: Gold nanoparticles enhance immunity, promotes antigen uptake by antigen-presenting cells (APCs), and boost the response against tumor antigens; therefore, they are a promising delivery vehicle. Tumor lysates have shown favorable responses as inductors of anti-cancer but effectiveness these treatments could be improved. Hybrid nanosystems gold with biomolecules been show alternative on uptake, activation immune system. Objectives: This study’s objective was to develop method synthesizing employing triple-negative breast cancer (4T1) cell lysate (AuLtNps) reducing agent increase immunogenicity cells. Methods: Nanoparticle formation, size, ζ potential were confirmed surface plasmon resonance, dynamic light scattering, transmission electron microscopy. Protein concentration quantified using Pierce BCA assay. The cytotoxic effects murine macrophages assessed, along nanoparticle via epifluorescence Using model, cytokine secretion profiles determined, efficacy in inhibiting implantation 4T1 model evaluated. Results/Conclusions: AuLtNps exhibited higher protein content than alone, leading increased phagocytosis macrophages, Cytokine analysis showed proinflammatory response, CD8+ CD22+ lymphocytes upregulation APC markers (CD14, CD80, CD86, MHC II+). Splenocytes demonstrated specific lysis up 40% In AuLtNPs effectively inhibited implantation, achieving an improved 90-days survival rate, highlighting their immunotherapy for cancer.

Language: Английский

---

Melanoma-associated fibroblasts in tumor-promotion flammation and antitumor immunity: novel mechanisms and potential immunotherapeutic strategies

Human Molecular Genetics, Journal Year: 2024, Volume and Issue: 33(13), P. 1186 - 1193

Published: March 27, 2024

Abstract Melanoma, renowned for its aggressive behavior and resistance to conventional treatments, stands as a formidable challenge in the oncology landscape. The dynamic complex interplay between cancer cells tumor microenvironment has gained significant attention, revealing Melanoma-Associated Fibroblasts (MAFs) central players disease progression. heterogeneity of MAFs endows them with dual role melanoma. This exhaustive review seeks not only shed light on multifaceted roles orchestrating tumor-promoting inflammation but also explore their involvement antitumor immunity. By unraveling novel mechanisms underlying MAF functions, this aims provide comprehensive understanding impact melanoma development. Additionally, it delves into potential leveraging innovative immunotherapeutic strategies, offering new avenues enhancing treatment outcomes challenging realm therapeutics.

Language: Английский

---

Exploring structure-directed immunogenic cytotoxicity of arginine-rich peptides for cytolysis-induced immunotherapy of cancer

Bioorganic & Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 116, P. 117984 - 117984

Published: Nov. 8, 2024

Language: Английский

---

Engineered immune cell-based therapeutics for female reproductive tract cancers: Advances and future prospects

Journal of Reproductive Healthcare and Medicine, Journal Year: 2024, Volume and Issue: 5, P. 14 - 14

Published: Nov. 28, 2024

Cancers of the reproductive tract are one major causes deaths in women. The higher rate mortality among these cancers mainly due to late stage disease detection and resistance existing drugs. As research progresses, personalized medicine, which involves tailoring treatments unique characteristics each patient’s tumor, is expected play a significant role future. Engineered immune cells such as engineered dendritic cells, chimeric antigen receptor (CAR) T-cells, natural killer (NK) have emerged an innovative approach cure female (FRCs). These designed boost system’s ability identify remove cancer offering new therapeutic opportunities for patients with limited treatment options. present review highlights applicability various cell-based approaches treat FRCs. It also outlines potential combining nanoparticle-based engineering strategies further enhance effectiveness cell through improving delivery modulators. Overall, article promising improve outcomes

Language: Английский

---

Immunoengineering a Future of Molecular, Material, and Cellular Therapeutics

The Journal of Immunology, Journal Year: 2024, Volume and Issue: 212(2), P. 167 - 168

Published: Jan. 2, 2024

Views Icon Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Facebook Twitter LinkedIn Email Tools Get Permissions Search Site Cite View This Citation Add to Manager Jeffrey A. Hubbell; Immunoengineering a Future of Molecular, Material, and Cellular Therapeutics. J Immunol 15 January 2024; 212 (2): 167–168. https://doi.org/10.4049/jimmunol.2300773 Download citation file: Ris (Zotero) Reference EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Dropdown Menu input auto suggest filter your All ContentThe Journal Immunology Advanced

Language: Английский

---